Work

Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis

Year: 2020

Type: conference-abstract

Source: European Respiratory Journal

DOI: 10.1183/13993003.congress-2020.984

Authors: Klaus F. Rabe, Fernando J. Martinez, Gary T. Ferguson, Chen Wang, Dave Singh, Jadwiga A. Wedzicha, Roopa Trivedi, Earl St Rose, Shaila Ballal, Julie Mclaren, Patrick Darken, Magnus Aurivillius, Colin Reisner, Paul Dorinsky

Institutions: Christian-Albrechts-Universität zu Kiel, German Center for Lung Research, LungenClinic Grosshansdorf, Weill Cornell Medicine, China-Japan Friendship Hospital, University of Manchester, Manchester University NHS Foundation Trust, Medicines Evaluation Unit, Imperial College London, AstraZeneca (United States), AstraZeneca (Sweden)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097319475

Cites:

Cited by: 2

Related to: 10